CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
MK-8226 BID, 1 mg +9 moredrug
Likely dose
MK-8226 BID, 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01096160
NCT01096160Phase 1Completed
CompareCT.gov

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8266

Merck Sharp & Dohme LLC·interventional·Posted Mar 30, 2010·Updated Aug 12, 2019

In Brief

A Phase 1 clinical trial evaluating MK-8226 BID, 1 mg, MK-8266 BID, 1.8 mg, and 7 other interventions for Hypertension. Completed, enrolled 40 participants.

Detailed Summary

This study evaluated adverse events (AEs), study discontinuation due to AEs, and pharmacodynamics of MK-8266 in male participants with mild to moderate hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 30, 2010
Enrollment StartMar 1, 2010
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.3 years ago

Interventions

MK-8226 BID, 1 mgdrug

MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.

MK-8266 BID, 1.8 mgdrug

MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.

MK-8266 TID, 1.8 mgdrug

MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.

MK-8266 TID, 2.4 mgdrug

MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.

MK-8266 TID, 2.4 mgdrug

MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.

Placebo BID (Panel A)drug

Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.

Placebo BID (Panel B)drug

Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.

Placebo TID (Panel C)drug

Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.

Placebo TID (Panel D)drug

Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.

Placebo TID (Panel E)drug

Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.